Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Merkel Cell × Etoposide × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 124 Lymphoma, Large B-Cell, Diffuse 77 Lymphoma, Non-Hodgkin 75 Small Cell Lung Carcinoma 70 Hodgkin Disease 57 Precursor Cell Lymphoblastic Leukemia-Lymphoma 54 Leukemia 53 Burkitt Lymphoma 52 Lung Neoplasms 46 Lymphoma, Follicular 43 Lymphoma, Mantle-Cell 39 Lymphoma, Large-Cell, Immunoblastic 38 Leukemia, Myeloid, Acute 37 Leukemia, Lymphocytic, Chronic, B-Cell 33 Multiple Myeloma 29 Carcinoma, Non-Small-Cell Lung 26 Recurrence 24 Lymphoma, B-Cell, Marginal Zone 24 Neuroblastoma 21 Central Nervous System Neoplasms 20 Ovarian Neoplasms 17 Sarcoma 16 Dendritic Cell Sarcoma, Interdigitating 16 Congenital Abnormalities 15 Breast Neoplasms 15 Brain Neoplasms 15 Neoplasms, Plasma Cell 14 Myelodysplastic Syndromes 13 Lymphoma, Large-Cell, Anaplastic 13 Neoplasms 12

Interventions

pembrolizumab 9 avelumab 9 Nivolumab 7 atezolizumab 4 durvalumab 3 Specimen Handling 3 Biopsy 3 ALT-803 3 talimogene laherparepvec 2 fludarabine phosphate 2 fludarabine 2 domatinostat 2 cemiplimab 2 Radiotherapy 2 Radiosurgery 2 Magnetic Resonance Spectroscopy 2 Ipilimumab 2 Cyclophosphamide 2 relatlimab 1 oblimersen 1 lutetium Lu 177 dotatate 1 lenvatinib 1 lanreotide 1 cabozantinib 1 aldesleukin 1 advexin 1 Radiation Dose Hypofractionation 1 Paclitaxel 1 Opdualag 1 Lidocaine, Prilocaine Drug Combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06086288 2023-10-17

PANDORA

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Not yet recruiting

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡